Steven M. Larson

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

Howard I. Scher, Tomasz M. Beer, Celestia S. Higano et al. · The Lancet · 2010 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

Alan L. Ho, Ravinder K. Grewal, Rébecca Leboeuf et al. · New England Journal of Medicine · 2013 · 829 citations · Full text

Medicine, Endocrinology, Nuclear Medicine +16

Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe

Evan H. Phillips, Oula Peñate Medina, Pat Zanzonico et al. · Science Translational Medicine · 2014 · 697 citations

Medicine, Oncology, Radiology +12

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Lalitha Shankar, John M. Hoffman, S.L. Bacharach et al. · PubMed · 2006 · 679 citations

Medicine, Nuclear Medicine, Oncology +17

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

Daniel C. Danila, Glenn Heller, Gretchen A. Gignac et al. · Clinical Cancer Research · 2007 · 673 citations

Medicine, Cancer Biology, Oncology +14